Last reviewed · How we verify
Pioglitazone + Metformin
Pioglitazone + Metformin is a Thiazolidinedione + Biguanide combination Small molecule drug developed by Sun Yat-sen University. It is currently FDA-approved for Type 2 diabetes mellitus.
This combination reduces blood glucose by improving insulin sensitivity through PPAR-γ activation (pioglitazone) and decreasing hepatic glucose production while improving peripheral glucose uptake (metformin).
This combination reduces blood glucose by improving insulin sensitivity through PPAR-γ activation (pioglitazone) and decreasing hepatic glucose production while improving peripheral glucose uptake (metformin). Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Pioglitazone + Metformin |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Thiazolidinedione + Biguanide combination |
| Target | PPAR-γ (pioglitazone); AMPK/mitochondrial complex I (metformin) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity in muscle and adipose tissue. Metformin is a biguanide that reduces hepatic gluconeogenesis and improves insulin-mediated glucose uptake in peripheral tissues. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Fluid retention / edema
- Gastrointestinal disturbance (nausea, diarrhea)
- Heart failure exacerbation
- Lactic acidosis (metformin-related, rare)
Key clinical trials
- The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD (PHASE4)
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (NA)
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes (PHASE3)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone + Metformin CI brief — competitive landscape report
- Pioglitazone + Metformin updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Pioglitazone + Metformin
What is Pioglitazone + Metformin?
How does Pioglitazone + Metformin work?
What is Pioglitazone + Metformin used for?
Who makes Pioglitazone + Metformin?
What drug class is Pioglitazone + Metformin in?
What development phase is Pioglitazone + Metformin in?
What are the side effects of Pioglitazone + Metformin?
What does Pioglitazone + Metformin target?
Related
- Drug class: All Thiazolidinedione + Biguanide combination drugs
- Target: All drugs targeting PPAR-γ (pioglitazone); AMPK/mitochondrial complex I (metformin)
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: Pioglitazone + Metformin vs similar drugs
- Pricing: Pioglitazone + Metformin cost, discount & access